New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite: Design, Synthesis, and Biopharmacological Properties
- 22 March 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (8) , 2628-2639
Abstract
In a preliminary work, we reported two NO−sartans, possessing the characteristics of an AT1 antagonist and a “slow NO donor”, obtained by adding NO-donor side chains to losartan 1. The NO release from an NO−sartan should be modulated in order to strengthen the antihypertensive activity of the native drug and to ensure additional effects, such as the antiplatelet and anti-ischemic ones. To obtain a collection of prototypical NO−sartans, showing different rates of NO release, new NO-donor moieties have been linked to 1 or its active metabolite 2 (EXP 3174). Almost all the synthesized compounds exhibited both AT1-antagonist and NO-mediated vasorelaxing properties, with a wide range of NO-releasing rates. Further pharmacological investigation on compound 4a showed that it possessed antihypertensive and cardiac antihypertrophic effects similar to those of the reference AT1-blocking or ACE-inhibiting drugs. Furthermore, the additional anti-ischemic cardio-protective properties and antiplatelet effects of 4a have been preliminarily investigated.Keywords
This publication has 16 references indexed in Scilit:
- Pharmacology and potential therapeutic applications of nitric oxide‐releasing non‐steroidal anti‐inflammatory and related nitric oxide‐donating drugsBritish Journal of Pharmacology, 2002
- Nitrosothiol Esters of Diclofenac: Synthesis and Pharmacological Characterization as Gastrointestinal-Sparing Prodrugs,Journal of Medicinal Chemistry, 2000
- PF9404C, a new slow NO donor with beta receptor blocking propertiesBritish Journal of Pharmacology, 1999
- NO-aspirins: a class of new anti-inflammatory and antithrombotic agentsTrends in Pharmacological Sciences, 1999
- Practical Considerations of the Pharmacology of Angiotensin Receptor BlockersThe Journal of Clinical Pharmacology, 1999
- Endothelial Dysfunction: From Physiology to TherapyJournal of Molecular and Cellular Cardiology, 1999
- NO‐Aspirins: Antithrombotic Activity of Derivatives of Acetyl Salicylic Acid Releasing Nitric OxideCardiovascular Drug Reviews, 1998
- New insights into mechanisms underlying nitrate toleranceThe American Journal of Cardiology, 1996
- In Vitro Pharmacology of a Novel Non-Peptide Angiotensin II-Receptor Antagonist, E4177The Japanese Journal of Pharmacology, 1993
- Prevention of Coronary Spasm by NicorandilJournal of Cardiovascular Pharmacology, 1992